Evidence map›Paper›PMID 40330470›Full record

ArticleFrontiers in immunology2025

Multi-omics identification of a polyamine metabolism related signature for hepatocellular carcinoma and revealing tumor microenvironment characteristics.

Yuexi Yu, Huiru Liu, Kaipeng Liu, Meiqi Zhao, Yiyan Zhang, Runci Jiang, Fengmei Wang

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yuexi YuDepartment of gastroenterology &hepatology, Tianjin First Center Hospital, Tianjin Key Laboratory for Organ Transplantation, Tianjin Key Laboratory of Molecular Diagnosis and Treatment of Liver Cancer, Tianjin Medical University, Tianjin, China.
Huiru LiuDepartment of gastroenterology &hepatology, Tianjin First Center Hospital, Tianjin Key Laboratory for Organ Transplantation, Tianjin Key Laboratory of Molecular Diagnosis and Treatment of Liver Cancer, Tianjin Medical University, Tianjin, China.
Kaipeng LiuDepartment of Hepatobiliary Oncology, Liver Cancer Center, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University, Tianjin, China.
Meiqi ZhaoDepartment of gastroenterology &hepatology, Tianjin First Center Hospital, Tianjin Key Laboratory for Organ Transplantation, Tianjin Key Laboratory of Molecular Diagnosis and Treatment of Liver Cancer, Nankai University, Tianjin, China.
Yiyan ZhangDepartment of gastroenterology &hepatology, Tianjin First Center Hospital, Tianjin Key Laboratory for Organ Transplantation, Tianjin Key Laboratory of Molecular Diagnosis and Treatment of Liver Cancer, Tianjin Medical University, Tianjin, China.
Runci JiangDepartment of gastroenterology &hepatology, Tianjin First Center Hospital, Tianjin Key Laboratory for Organ Transplantation, Tianjin Key Laboratory of Molecular Diagnosis and Treatment of Liver Cancer, Tianjin Medical University, Tianjin, China.
Fengmei WangDepartment of gastroenterology &hepatology, Tianjin First Center Hospital, Tianjin Key Laboratory for Organ Transplantation, Tianjin Key Laboratory of Molecular Diagnosis and Treatment of Liver Cancer, Tianjin Medical University, Tianjin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Accumulating evidence indicates that elevated polyamine levels are closely linked to tumor initiation and progression. However, the precise role of polyamine metabolism in hepatocellular carcinoma (HCC) remains poorly understood. Methods: We conducted differential expression analysis on bulk RNA sequencing data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) to identify 65 polyamine metabolism-related genes. By employing unsupervised consensus clustering, AddModuleScore, single-sample gene set enrichment analysis (ssGSEA), and weighted gene co-expression network analysis (WGCNA), we identified polyamine metabolism-related genes at both the bulk RNA-seq and single-cell RNA-seq (scRNA-seq) levels. Utilizing 101 machine learning algorithms, we constructed a polyamine metabolism-related signature (PMRS) and validated its predictive power across training, testing, and external validation cohorts. Additionally, we developed a prognostic nomogram model by integrating PMRS with clinical variables. To explore immune treatment sensitivity, we assessed tumor mutation burden (TMB), tumor immune dysfunction and exclusion (TIDE) score, mutation frequency, and immune checkpoint genes expression. Immune cell infiltration was analyzed using the CIBERSORT algorithm. Finally, RT-qPCR experiments were conducted to validate the expression of key genes. Results: Using 101 machine learning algorithms, we established a polyamine metabolism-related signature comprising 9 genes, which exhibited strong prognostic value for HCC patients. Further analysis revealed significant differences in clinical features, biological functions, mutation profiles, and immune cell infiltration between high-risk and low-risk groups. Notably, TIDE analysis and immune phenotype scoring (IPS) demonstrated distinct immune treatment sensitivities between the two risk groups. RT-qPCR validation confirmed that these 9 genes were highly expressed in normal cells but significantly downregulated in tumor cells. Conclusions: Our study developed a polyamine metabolism-based prognostic risk signature for HCC, which may provide valuable insights for personalized treatment strategies in HCC patients.

Indexed as

Biomarkers, TumorCarcinoma, HepatocellularLiver NeoplasmsPolyaminesTumor MicroenvironmentFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMachine LearningMaleMultiomicsPrognosisTranscriptomeBiomarkers, TumorPolyamineshepatocellular carcinomaimmune therapymachine learningmulti-omics analysispolyamine metabolismsingle-cell RNA sequencing

Identifiers

PMID40330470
PMCPMC12052762

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.